Gyre Therapeutics (GYRE) Short-term Investments (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Short-term Investments for 15 consecutive years, with $12.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments fell 16.89% year-over-year to $12.3 million; the TTM figure through Mar 2026 stood at $12.3 million (down 16.89% YoY), while the FY2025 annual figure was $15.4 million, up 3.65% from the prior year.
• Short-term Investments declined to $12.3 million in Q1 2026 per GYRE's latest filing, from $15.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $19.6 million in Q3 2025 and bottomed at $7.6 million in Q1 2024.
• Historically, Short-term Investments has averaged $13.4 million across 3 years, with a median of $14.8 million in 2025.
• Annual changes were most pronounced in 2025 — Short-term Investments surged 112.44% — and 2026, when it retreated 16.89%.
• Gyre Therapeutics' Short-term Investments stood at $14.9 million in 2024, then increased by 3.65% to $15.4 million in 2025, then slipped by 20.13% to $12.3 million in 2026.
• Business Quant data shows GYRE's Short-term Investments at $12.3 million in Q1 2026, $15.4 million in Q4 2025, and $19.6 million in Q3 2025.